IAA Journal of Scientific Research 11(3):32-35, 2024. www.iaajournals.org
©IAAJOURNALS ISSN: 2636-7319
https://doi.org/10.59298/IAAJSR/2024/113.3235 IAAJSR:113.3235

Brown and Beige Fat Activation as Therapeutic Targets in Obesity-Associated Dyslipidemia

Katu Amina H.

School of Natural and Applied Sciences Kampala International Uganda

ABSTRACT

Obesity is a global health challenge that significantly increases the risk of dyslipidemia, characterized by abnormal lipid levels, and is a major contributor to cardiovascular diseases (CVD). Emerging evidence suggests that the activation of brown adipose tissue (BAT) and beige adipose tissue (BeAT), both of which possess thermogenic capacities, may offer novel therapeutic avenues for combating obesity and dyslipidemia. Unlike white adipose tissue (WAT), which stores energy, BAT and BeAT play pivotal roles in energy expenditure, lipid metabolism, and glucose homeostasis. This review delves into the physiological roles of brown and beige fat, their contribution to lipid metabolism, and the mechanisms underlying their activation. We discuss the molecular pathways involved in the browning of white fat and how these processes can be harnessed to treat obesity-associated dyslipidemia. Furthermore, we explore pharmacological and non-pharmacological strategies to activate BAT and BeAT, focusing on potential clinical applications. The challenges and future directions for brown and beige fat activation as therapeutic targets in metabolic diseases are also outlined.

Keywords: Obesity; Dyslipidemia; Brown adipose tissue (BAT); Beige adipose tissue (BeAT); Lipid metabolism

INTRODUCTION

Obesity is a multifaceted disorder marked by excessive fat accumulation and associated with several metabolic dysfunctions, including insulin resistance, hyperglycemia, and dyslipidemia[1–3]. Dyslipidemia, specifically elevated levels of triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and reduced high-density lipoprotein cholesterol (HDL-C), is a key risk factor for cardiovascular diseases (CVD) in obese individuals.[4–6] While conventional treatments for obesity-associated dyslipidemia focus on lifestyle modifications and pharmacotherapy, new strategies targeting adipose tissue dynamics hold promise for more effective management. Among these is the activation of brown and beige fat, which has gained attention due to its unique metabolic properties, particularly its role in thermogenesis and lipid metabolism.

Brown and Beige Fat: Distinct and Overlapping Roles

Brown Adipose Tissue (BAT): BAT is primarily found in the interscapular region and is characterized by its high mitochondrial content and expression of uncoupling protein 1 (UCP1), which drives non-shivering thermogenesis. BAT activation increases energy expenditure and improves lipid utilization, making it a potential target for metabolic interventions[7–9].

Beige Adipose Tissue (BeAT): BeAT, or inducible brown fat, is found within WAT depots and can be recruited through "browning" processes triggered by environmental factors such as cold exposure, exercise, and certain pharmacological agents. BeAT exhibits a similar thermogenic profile to BAT and plays a key role in enhancing lipid oxidation and glucose metabolism[10–12].

Mechanisms of Brown and Beige Fat Activation

The activation of brown and beige fat is tightly regulated by several molecular pathways:

Sympathetic Nervous System (SNS) Activation: The SNS, via β-adrenergic receptor stimulation, is one of the most potent activators of BAT and BeAT. Norepinephrine binding to β3-adrenergic receptors initiates a cascade that leads to UCP1 expression and subsequent thermogenesis[13, 14].

PGC-1α Pathway: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a master regulator of mitochondrial biogenesis and thermogenesis in brown and beige adipocytes. Its activation is crucial for the induction of UCP1 and the overall thermogenic program[15, 16].

Irisin and Fibroblast Growth Factor 21 (FGF21): These hormones play pivotal roles in the browning of WAT. Irisin, released during exercise, promotes the conversion of white fat into beige fat, while FGF21 enhances lipid oxidation and energy expenditure[17, 18].

PPARγ Agonism: Peroxisome proliferator-activated receptor gamma (PPARγ) is a key transcription factor that regulates adipocyte differentiation and lipid metabolism. PPARγ agonists have been shown to promote browning in WAT and improve lipid profiles.[19]

Brown and Beige Fat in Lipid Metabolism

Brown and beige fat activation not only increases energy expenditure but also has direct effects on lipid metabolism. These tissues play a crucial role in triglyceride clearance and fatty acid oxidation. Studies have shown that increased BAT activity is associated with lower circulating levels of triglycerides and LDL-C, while elevating HDL-C levels, thus mitigating dyslipidemia[20].

Therapeutic Activation of Brown and Beige Fat in Obesity-Associated Dyslipidemia

Pharmacological Approaches:

β3-adrenergic Agonists: Drugs targeting β3-adrenergic receptors have shown promise in activating BAT and BeAT. Mirabegron, a β3-agonist used to treat overactive bladder, has been found to stimulate BAT thermogenesis and improve lipid profiles in humans[21, 22].

PPARγ Agonists: Thiazolidinediones, such as rosiglitazone, activate PPARγ and have been shown to induce browning of WAT, improving lipid metabolism in obesity[23].

Non-Pharmacological Strategies:

Cold Exposure: Cold-induced thermogenesis is a well-established method of BAT activation. Studies indicate that regular cold exposure can increase BAT activity and enhance lipid oxidation, thereby improving dyslipidemia [24, 25].

Exercise: Exercise-induced browning of WAT through the secretion of irisin is another promising approach. Regular physical activity not only enhances BeAT activation but also promotes better lipid profiles and overall metabolic health[26].

Dietary Interventions: Nutritional components such as capsaicin, found in chili peppers, and resveratrol, a polyphenol in red grapes, have been shown to activate BAT and promote browning of WAT, contributing to lipid metabolism improvement[27].

Challenges and Future Directions

While the activation of brown and beige fat presents a novel strategy for combating obesity and dyslipidemia, several challenges remain. The efficacy and safety of long-term pharmacological activation need further investigation. Moreover, identifying patient populations that would most benefit from these therapies is essential. Future research should focus on optimizing strategies for brown and beige fat activation, exploring combination therapies, and investigating the genetic factors that may influence responsiveness to these interventions.

CONCLUSION

The activation of brown and beige adipose tissues holds significant therapeutic potential for addressing obesity-associated dyslipidemia. By enhancing lipid metabolism and energy expenditure, these fat depots offer a promising target for novel interventions. As our understanding of the molecular mechanisms governing brown and beige fat activation expands, so too will the potential for translating these findings into effective clinical therapies for obesity and metabolic diseases.

REFERENCES

1. Calcaterra, V., Verduci, E., Milanta, C., Agostinelli, M., Bona, F., Croce, S., Valsecchi, C., Avanzini, M.A., Zuccotti, G.: The Benefits of the Mediterranean Diet on Inflamm-Aging in Childhood Obesity. Nutrients. 16, 1286 (2024). https://doi.org/10.3390/nu16091286
2. Camilleri, M., Acosta, A.: Combination Therapies for Obesity. Metab Syndr Relat Disord. 16, 390–394 (2018). https://doi.org/10.1089/met.2018.0075
3. Caslin, H.L., Bhanot, M., Bolus, W.R., Hasty, A.: Adipose tissue macrophages: unique polarization and bioenergetics in obesity. Immunol Rev. 295, 101–113 (2020). https://doi.org/10.1111/imr.12853
4. Uti, D.E., Ibiam, U.A., Omang, W.A., Udeozor, P.A., Umoru, G.U., Nwadum, S.K.,

Bawa, I., Alum, E.U., Mordi, J.C., Okoro, E.O., Obeten, U.N., Onwe, E.N., Zakari, S., Opotu, O.R., Aja, P.M.: Buchholzia coriacea Leaves Attenuated Dyslipidemia and Oxidative Stress in Hyperlipidemic Rats and Its Potential Targets In Silico. Pharmaceutical Fronts. 05, e141–e152 (2023). https://doi.org/10.1055/s-0043-1772607

5. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Rotimi, S.O., Nna, V.U.: African Walnuts (Tetracarpidium conophorum) Modulate Hepatic Lipid Accumulation in Obesity via Reciprocal Actions on HMG-CoA Reductase and Paraoxonase. Endocrine, Metabolic & Immune Disorders - Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders). 20, 365–379 (2020). https://doi.org/10.2174/1871530319666190724114729
6. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Nna, V.U., Udeozor, P.A.: African walnuts attenuate ectopic fat accumulation and associated peroxidation and oxidative stress in monosodium glutamate-obese Wistar rats. Biomedicine & Pharmacotherapy. 124, 109879 (2020). https://doi.org/10.1016/j.biopha.2020.109879
7. Maliszewska, K., Kretowski, A.: Brown Adipose Tissue and Its Role in Insulin and Glucose Homeostasis. Int J Mol Sci. 22, 1530(2021). https://doi.org/10.3390/ijms22041530
8. Jung, S.M., Sanchez-Gurmaches, J., Guertin, D.A.: Brown Adipose Tissue Development and Metabolism. Handb Exp Pharmacol. 251,3–36(2019). https://doi.org/10.1007/164_2018_168
9. Wankhade, U.D., Shen, M., Yadav, H., Thakali, K.M.: Novel Browning Agents, Mechanisms, and Therapeutic Potentials of Brown Adipose Tissue. BioMed Research International. 2016, 2365609 (2016). https://doi.org/10.1155/2016/2365609
10. Pilkington, A.-C., Paz, H.A., Wankhade, U.D.: Beige Adipose Tissue Identification and Marker Specificity—Overview. Front Endocrinol (Lausanne). 12, 599134 (2021). https://doi.org/10.3389/fendo.2021.599134
11. Cheng, L., Wang, J., Dai, H., Duan, Y., An, Y., Shi, L., Lv, Y., Li, H., Wang, C., Ma, Q., Li, Y., Li, P., Du, H., Zhao, B.: Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. Adipocyte. 10, 48–65. https://doi.org/10.1080/21623945.2020.1870060
12. Nedergaard, J., Cannon, B.: The Browning of White Adipose Tissue: Some Burning Issues. Cell Metabolism. 20, 396–407 (2014). https://doi.org/10.1016/j.cmet.2014.07.005
13. Ueta, C.B., Fernandes, G.W., Capelo, L.P., Fonseca, T.L., D'Angelo Maculan, F., Gouveia, C.H.A., Brum, P.C., Christoffolete, M.A., Aoki, M.S., Lancellotti, C.L., Kim, B., Bianco, A.C., Ribeiro, M.O.: β1 Adrenergic receptor is key to cold- and diet-induced thermogenesis in mice. J Endocrinol. 214, 359–365 (2012). https://doi.org/10.1530/JOE-12-0155
14. Pasha, A., Tondo, A., Favre, C., Calvani, M.: Inside the Biology of the β3-Adrenoceptor. Biomolecules. 14, 159 (2024). https://doi.org/10.3390/biom14020159
15. Abu Shelbayeh, O., Arroum, T., Morris, S., Busch, K.B.: PGC-1α Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response. Antioxidants (Basel). 12, 1075 (2023). https://doi.org/10.3390/antiox12051075
16. Qian, L., Zhu, Y., Deng, C., Liang, Z., Chen, J., Chen, Y., Wang, X., Liu, Y., Tian, Y., Yang, Y.: Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases. Sig Transduct Target Ther. 9, 1–44 (2024). https://doi.org/10.1038/s41392-024-01756-w
17. Cuevas-Ramos, D., Mehta, R., Aguilar-Salinas, C.A.: Fibroblast Growth Factor 21 and Browning of White Adipose Tissue. Front Physiol. 10, 37 (2019). https://doi.org/10.3389/fphys.2019.00037
18. Mu, W.-J., Zhu, J.-Y., Chen, M., Guo, L.: Exercise-Mediated Browning of White Adipose Tissue: Its Significance, Mechanism and Effectiveness. Int J Mol Sci. 22, 11512 (2021). https://doi.org/10.3390/ijms222111512
19. Wu, H., Li, X., Shen, C.: Peroxisome Proliferator-Activated Receptor γ in White and Brown Adipocyte Regulation and Differentiation. Physiol Res. 759–773 (2020).

https://doi.org/10.33549/physiolres.934411
20. Magro, B.S., Dias, D.P.M.: Brown and beige adipose tissue: New therapeutic targets for metabolic disorders. Health Sciences Review. 10, 100148 (2024). https://doi.org/10.1016/j.hsr.2024.100148
21. Dąbrowska, A.M., Dudka, J.: Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug. J Clin Med. 12, 6897 (2023). https://doi.org/10.3390/jcm12216897
22. Cypess, A.M., Weiner, L.S., Roberts-Toler, C., Franquet Elía, E., Kessler, S.H., Kahn, P.A., English, J., Chatman, K., Trauger, S.A., Doria, A., Kolodny, G.M.: Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. Cell Metab. 21, 33–38 (2015). https://doi.org/10.1016/j.cmet.2014.12.009
23. Kroon, T., Harms, M., Maurer, S., Bonnet, L., Alexandersson, I., Lindblom, A., Ahnmark, A., Nilsson, D., Gennemark, P., O'Mahony, G., Osinski, V., McNamara, C., Boucher, J.: PPARγ and PPARα synergize to induce robust browning of white fat in vivo. Mol Metab. 36, 100964 (2020). https://doi.org/10.1016/j.molmet.2020.02.007
24. Huo, C., Song, Z., Yin, J., Zhu, Y., Miao, X., Qian, H., Wang, J., Ye, L., Zhou, L.: Effect of Acute Cold Exposure on Energy Metabolism and Activity of Brown Adipose Tissue in Humans: A Systematic Review and Meta-Analysis. Frontiers in Physiology. 13, (2022). https://doi.org/10.3389/fphys.2022.917084
25. Saito, M., Yoneshiro, T., Matsushita, M.: Activation and recruitment of brown adipose tissue by cold exposure and food ingredients in humans. Best Practice & Research Clinical Endocrinology & Metabolism. 30, 537–547(2016). https://doi.org/10.1016/j.beem.2016.08.003
26. Zhu, Y., Qi, Z., Ding, S.: Exercise-Induced Adipose Tissue Thermogenesis and Browning: How to Explain the Conflicting Findings? Int J Mol Sci. 23, 13142 (2022). https://doi.org/10.3390/ijms232113142
27. Noriega, L., Yang, C.-Y., Wang, C.-H.: Brown Fat and Nutrition: Implications for Nutritional Interventions. Nutrients. 15, 4072(2023). https://doi.org/10.3390/nu15184072

CITE AS: Katu Amina H. (2024). Brown and Beige Fat Activation as Therapeutic Targets in Obesity-Associated Dyslipidemia. IAA Journal of Scientific Research 11(3):32-35. https://doi.org/10.59298/IAAJSR/2024/113.3235